Immuno-oncology

The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.

Latest News

FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

March 14th 2024

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

Image credit: wladimir1804 | stock.adobe.com
FDA Approves Shorter Manufacturing Process for CAR T-cell Therapy Axicabtagene Ciloleucel

January 31st 2024

catalin - stock.adobe.com
Neoadjuvant Nivolumab May Boost Survival Outcomes in Patients With Renal Cell Carcinoma

January 30th 2024

Image credit: peterschreiber.media | stock.adobe.com
ADC Drug Candidate Enters Phase 3 Trial for the Treatment of HER2-Low Breast Cancer

January 25th 2024

Image Credit: © wladimir1804 - stock.adobe.com
FDA Updates Label for Axicabtagene Ciloleucel for R/R LBCL Following Positive Long-Term Survival Data

December 22nd 2023

Video Interviews
Latest CME Events & Activities

Drug Resistance and Toxicity Mitigation Strategies: Optimizing the Role of the Pharmacist in Management of Patients With Chronic Myeloid Leukemia

2.0 Credits / Oncology

View More

Risks and Liabilities in Pharmacy Practice

1.0 Credit / Law

View More

Exploring the New Standard of Care for the Frontline Treatment of Non-Small Cell Lung Cancer: A Focus on Immunotherapy

1.5 Credits / Oncology, Pulmonology/Respiratory

View More

Optimizing the Use of Targeted Therapies for the Treatment of ROS1-Rearranged and KRAS-Mutant Non−Small Cell Lung Cancer

1.0 Credits / Oncology

View More

2022 ASH Annual Meeting Coverage—Recent Developments in Diffuse Large B-Cell Lymphoma: Insights and Application for Managed Care

1.0 Credit / Oncology

View More

An Article in the American Journal of Managed Care’s Evidence-Based Oncology: Navigating the Complexities of Frontline Immunotherapy in NSCLC

2 Credits / Oncology, Pulmonology/Respiratory

View More

CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care

1.5 Credits / Hematology, Oncology

View More

Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL

2.0 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma

1.5 Credits / Hematology, Oncology

View More

Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia

1.5 Credits / Hematology, Oncology

View More

New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes

1.5 Credits / Hematology, Oncology

View More

Evidence and Managed Care Considerations for the Use of Novel Immunotherapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1.5 Credits / Oncology

View More

Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care

1.0 Credit / Hematology, Oncology

View More

Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens

1.0 Credit / Hematology, Oncology

View More

Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy

1.0 Credit / Hematology, Oncology

View More

Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role

1.0 Credit / Hematology, Oncology

View More

Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives

1.0 Credit / Hematology, Oncology

View More

Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens

1.0 Credit / Hematology, Oncology

View More

Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions

1.0 Credit / Oncology

View More

Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure

1.0 Credit / Oncology

View More

Optimizing Treatment of Early-Stage Breast Cancer and the Pharmacist’s Role in Managing Targeted Therapies

1.5 Credits / Oncology

View More

Targeted Therapies for Non-Small Cell Lung Cancer With ROS1 or KRAS Mutations and the Impact of Pharmacists’ Care

1.0 Credit / Oncology, Pulmonology/Respiratory

View More

Enhancing Care for Patients With Endometrial Cancer Through Pharmacist Interventions

1.0 Credit / Oncology, Women’s Health

View More

Investigating Novel Strategies for the Treatment of Metastatic Small Cell Lung Cancer After Frontline Treatment Failure

1.0 Credit / Oncology

View More

Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies

1.5 Credits / Hematology, Oncology

View More

Clinical Updates and Strategies for Optimizing Use of Bispecific Antibodies in Hematologic Malignancies

1.0 Credit / Oncology

View More

Perspectives on Emerging Data for the Use of Immunotherapy in the Treatment of Early-Stage Non-Small Cell Lung Cancer

1.5 Credits / Oncology, Pulmonology/Respiratory

View More

Promoting Adherence in Early-Stage HR+/HER2- Breast Cancer: The Value of Oncology Pharmacists in Preventing Premature Treatment Discontinuation

1.25 Credit(s) / Oncology; Women’s Health

View More

Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies

1.0 Credits / Hematology, Oncology

View More

Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team

1.5 Credits / Hematology, Oncology

View More

More News

© 2024 MJH Life Sciences

All rights reserved.